OBX · Obsidian Therapeutics, Inc. · Shareholders & Ownership
Every disclosed holder of OBX in one list: 13F institutions, Schedule 13D and 13G filers, insiders (Forms 3, 4 and 5) and registered funds, each from its own latest filing. Holders nest by CIK and SEC reporting links, never by name, and each is summed once.
Who Owns OBX
| Holder group | Shares | % Out |
|---|---|---|
| Institutional (13F) | 0 | 0.00% |
| Insiders (Forms 3, 4, 5) | 30,937 | 0.05% |
| 13D/G-only blocks | 19,140,863 | 30.99% |
| Remaining | 42,601,076 | 68.96% |
| Registered funds (N-PORT, not summed) | 0 | 0.00% |
Shares outstanding: 61,772,876, the issuer's latest cover-page count restated onto today's split basis.
13D/G-only counts each filer's latest 13D or 13G that no 13F report of the listing contains, that names no 13F filer and that no counted insider files. Funds are never summed: their shares sit inside their advisers' 13F reports.
Holders of OBX
| # | Holder | Shares | As of | Notes |
|---|---|---|---|---|
| 1 |
RA CAPITAL MANAGEMENT, L.P.
13G
CIK 1346824 · Registered investment adviser · Aug 3, 2026
Rule 13d-1(c), passive investor
|
5,957,103 | ||
| 2 |
Paradigm Biocapital Advisors LP
13G
CIK 1855655 · Registered investment adviser · Sep 28, 2026
Rule 13d-1(c), passive investor
|
4,101,576 | ||
| 3 |
Deep Track Capital, LP
13G
CIK 1856083 · Investment adviser · Aug 4, 2026
Rule 13d-1(c), passive investor
|
3,315,605 | ||
| 4 |
|
3,123,992 | ||
| 5 |
|
2,642,587 | ||
| 6 |
|
30,937 |
Shares are restated onto today's split basis. Change compares each row with the same holder's previous filing in the same source; a dash means there is none to compare. Nested 13D/G, insider and fund rows are not summed, since a 13F report already holds them.